Pfizer was a major player in the development of the Covid-19 vaccines, but are they a good investment now?

We kicked off September in style!  The stock market finally dropped for the week.  The S&P 500 finished down 3.91% and is now well below 5,500. 

When it comes to the pharmaceutical industry, Pfizer stands tall as a legacy company with a rich history of innovation. However, its recent financial performance and stock price movements have left investors questioning its valuation. At a market cap of $124 billion and a trading price of $22 per share, is Pfizer undervalued, or does the dip signal deeper challenges?